Unexpectedly, the major determinant for these effects on quiescent CML-LSCs was the PP2A-induced inactivation of JAK2 and β-catenin, and not BCR-ABL1 inactivation. The gene discussed is JAK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.